HR-2839-119
Referred to the House Committee on Agriculture.
Sponsored by Randy Feenstra (R-IA)
What it does
This bill would reauthorize the Agricultural Genome to Phenome Initiative (AG2PI), a competitive grant program administered by the National Institute of Food and Agriculture (NIFA), through fiscal year 2030. The program funds research aimed at expanding scientific understanding of how the genetic makeup (genome) of crops and livestock translates into observable traits (phenome) — such as yield, disease resistance, and drought tolerance. It would also support coordination of that research across institutions.
Who benefits
Agricultural researchers and universities that compete for and receive grants. Public and private plant and animal breeders who could apply findings to develop improved crop varieties and livestock breeds. Farmers who may eventually benefit from crops and animals with improved traits such as higher yields or greater resilience. Agribusiness companies that develop and sell seeds, livestock genetics, and related products. Rural communities that depend on agricultural productivity. Consumers who may benefit indirectly from more stable or lower-cost food supplies if research yields productivity gains.
Who is hurt
Researchers and institutions that apply for grants but are not selected under the competitive process. Other NIFA programs that may compete for the same discretionary funding pool if appropriations are constrained. Taxpayers who bear the cost of the program. Agricultural biotechnology companies that do not receive grants may face competitive disadvantage relative to grant recipients who gain publicly funded research insights.
Supporters argue
Supporters argue that understanding the genome-to-phenome relationship is foundational to developing crops and livestock that can withstand climate variability, resist disease, and feed a growing global population — challenges that private industry alone has insufficient incentive to fund at the basic research level. They contend that NIFA's competitive grant structure ensures funds flow to the highest-quality science, and that reauthorizing through 2030 provides the multi-year continuity that long-term biological research requires to produce meaningful results.
Opponents argue
Opponents argue that the federal government should not continue funding research that the private agricultural biotechnology sector — a multi-billion-dollar industry — is already conducting, and that reauthorizing the program without a rigorous review of prior grant outcomes or measurable benchmarks risks perpetuating spending with unclear public return. They contend that without new authorization levels, performance metrics, or structural changes, this reauthorization is a routine extension that bypasses accountability for how previous AG2PI funds were used.
Constitutional context
No significant constitutional issue is raised by this bill. Congress has broad authority to fund scientific research and administer grant programs under the Spending Clause (Art. I, §8, cl. 1) and the Necessary and Proper Clause (Art. I, §8, cl. 18). Competitive grant programs of this type are well within established congressional authority and do not implicate active areas of constitutional dispute.
Checks and balances
Congress retains authority by setting the reauthorization period and program scope; the executive branch, through NIFA, administers the competitive grant process; annual appropriations by Congress serve as the primary check on program spending levels.
Historical precedent
The AG2PI was originally authorized under the Agriculture Improvement Act of 2018 (the 2018 Farm Bill); this bill would extend that existing program, following the standard pattern of periodic reauthorization of NIFA competitive grant programs.